APP and Alzheimer disease: Consequently, the outcome is identical to that depicted in Figure 16A. Following its transient depletion, accumulation of iAβ, now produced only by AβPP proteolysis, resumes from a low baseline and, provided no additional unconventional activations of the AβPP-independent iAβ production pathway would take place, neither the T1 crossing would occur, nor would AD recur within the lifespan of the treated individual.